Bepiastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H17N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35QK773Y96, chemically known as 6-(2-(dimethylamino)ethyl)pyrido(2,3-b)(1,5)benzothiazepin-5(6h)-one but generally known as bepiastine, which bears US NIH Compound Identifier 185456. European Medicines Agency schedules Bepiastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05777MIG. The term BEPIASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). BEPIASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bepiastine under HS 29349990 and SITC 51579. As of Q4 2014, BEPIASTINE remains the US FDA Preferred Term for this commodity. Bepiastine bears US NLM identifiers UMLS ID C2347002 and NCI Concept Code C73044. SMILES: S1C2C(N(CCN(C)C)C(=O)C3C1NCCC3)CCCC2.